Bristol-Myers highlights increased cholesterol awareness as benefit of Questran switch.
This article was originally published in The Tan Sheet
Executive Summary
BRISTOL HIGHLIGHTS CHOLESTEROL EDUCATION RESULTING FROM QUESTRAN SWITCH in making its case for approval of the switch application during a joint meeting of the Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees on Sept. 27. "We need to focus more educational effort on the professional as well as the consumer, and the over-the-counter product availability is going to make that possible," Virgil Brown, MD, Emory University School of Medicine, said in a presentation to the committee on behalf of Bristol-Myers Squibb.